

# SUSPECT ADVERSE REACTION REPORT

## I. REACTION INFORMATION

1. PATIENT INITIALS (first, last) <b>RFP</b>	1a. COUNTRY <b>COSTA RICA</b>	2. DATE OF BIRTH			2a. AGE <b>66</b> Years	3. SEX <b>Female</b>	3a. WEIGHT <b>70.00</b> kg	4-6 REACTION ONSET			8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION
		Day <b>29</b>	Month <b>AUG</b>	Year <b>1958</b>				Day	Month <b>Unk</b>	Year	
<p>7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data) Event Verbatim [PREFERRED TERM] (Related symptoms if any separated by commas)</p> <p>She forgets things [Memory impairment] Insomnia disorder [Insomnia] Blood pressure problems [Blood pressure abnormal] She becomes very nervous [Nervousness] She has a condition that causes her hands to move [Movement disorder]</p> <p>Case Description: This non-serious post market survey report originated from Costa Rica was received by Viatrix on 10-Jun-2025 (Local Ref No: VIA-2025-CR-0005).</p> <p style="text-align: right;">(Continued on Additional Information Page)</p>											
											<input type="checkbox"/> PATIENT DIED  <input type="checkbox"/> INVOLVED OR PROLONGED INPATIENT HOSPITALISATION <input type="checkbox"/> INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR INCAPACITY  <input type="checkbox"/> LIFE THREATENING <input type="checkbox"/> CONGENITAL ANOMALY  <input type="checkbox"/> OTHER

## II. SUSPECT DRUG(S) INFORMATION

14. SUSPECT DRUG(S) (include generic name) #1 ) Lipitor 40 mg (ATORVASTATIN) Tablet, 40 milligram #2 ) Clonazepam (Clonazepam) Unknown		20. DID REACTION ABATE AFTER STOPPING DRUG?  <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA
15. DAILY DOSE(S) #1 ) UNK #2 ) UNK	16. ROUTE(S) OF ADMINISTRATION #1 ) UNK #2 ) Oral use	
17. INDICATION(S) FOR USE #1 ) Cholesterol (Blood cholesterol abnormal) #2 ) Insomnia (Insomnia)		21. DID REACTION REAPPEAR AFTER REINTRODUCTION?  <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA
18. THERAPY DATES(from/to) #1 ) Ongoing #2 ) Unknown	19. THERAPY DURATION #1 ) Unknown #2 ) Unknown	

## III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction) #1 ) Vitamin b12 (Cyanocobalamin) Unknown ; Ongoing		
23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)		
From/To Dates Unknown to Ongoing Unknown to Ongoing	Type of History / Notes Current Condition Current Condition	Description Blood cholesterol abnormal (Blood cholesterol abnormal) Insomnia (Insomnia)

## IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER MYLANLABS Balwant Heer Building 4, Trident Place, Mosquito Way Hatfield, Hertfordshire AL10 9UL UNITED KINGDOM Phone: 44 01707853232		26. REMARKS Medically Confirmed: No World Wide #: CR-MYLANLABS-2025M1049722 Study ID: 9790
	24b. MFR CONTROL NO. <b>2025M1049722</b>	25b. NAME AND ADDRESS OF REPORTER R F P          COSTA RICA
24c. DATE RECEIVED BY MANUFACTURER <b>10-JUN-2025</b>	24d. REPORT SOURCE <input checked="" type="checkbox"/> STUDY <input type="checkbox"/> LITERATURE <input type="checkbox"/> HEALTH PROFESSIONAL <input type="checkbox"/> OTHER:	
DATE OF THIS REPORT <b>17-JUN-2025</b>	25a. REPORT TYPE <input checked="" type="checkbox"/> INITIAL <input type="checkbox"/> FOLLOWUP:	

17-Jun-2025 01:35

**ADDITIONAL INFORMATION****7+13. DESCRIBE REACTION(S) continued**

The patient participated in 9790: Increase adherence of our chronic patients by ensuring proper patient stay on treatment and compliance. Our Program is designed to accompany the patient and provide benefits throughout their treatment.

This initial case, received from consumer, non-health professional in Costa Rica, involved a 66-years-old female patient who reportedly experienced memory impairment, insomnia, blood pressure abnormal, nervousness, movement disorder while receiving Lipitor 40 mg (atorvastatin).

Medical history was not reported.

Current conditions included blood cholesterol abnormal, insomnia and memory impairment.

Concomitant medication included vitamin b12 (cyanocobalamin).

Non company suspect drug included clonazepam.

Unknown date: The patient initiated atorvastatin 40 milligram tablet at an unknown dose, unit and frequency via unknown route (batch/lot number and expiration date was unknown) for cholesterol and clonazepam unknown formulation at an unknown dose, unit and frequency via oral route (batch/lot number and expiration date was unknown) for insomnia. The patient indicated that she stopped taking Lipitor 40 mg three years ago, but after blood tests, high cholesterol was detected, and she had to restart the medication. She also mentioned that she forgets things, which has happened progressively over the years. She also reported that she has an insomnia disorder, which was why she sometimes goes to bed around 2 or 3 in the morning and sleeps during the day, and that this situation was taking a toll on her health. She also indicated that she was undergoing psychiatric treatment because she becomes very nervous, and that she has a condition that causes her hands to move and has blood pressure problems. The patient also indicated that she takes several medications and believes that the ones that may be affecting her health are the generic products she receives from the clinic, specifically clonazepam. Laboratory data included blood cholesterol was high and blood pressure measurement was abnormal.

No action was taken with atorvastatin in response to the events.

Action taken with clonazepam was unknown.

On 10-Jun-2025, at the time of reporting the patient had not yet recovered from the events memory impairment, insomnia, blood pressure abnormal, nervousness, movement disorder.

Case Comment: Reporter assessed causality as unrelated for memory impairment, insomnia, blood pressure abnormal, nervousness and movement disorder.

Company Comment: Non-Serious: Memory impairment, insomnia, blood pressure abnormal, nervousness and movement disorder are unlisted events as per company RSI of atorvastatin. Causality has been assessed as possible for events memory impairment, insomnia, blood pressure abnormal, nervousness and movement disorder, as contributory role of suspect drug cannot be completely excluded as per available information. Non company suspect and existing medical condition could be a cofounder in this case.

**13. Lab Data**

#	Date	Test / Assessment / Notes	Results	Normal High / Low
1		Blood cholesterol		
		High		
2		Blood pressure measurement		
		Abnormal		

**13. Relevant Tests**

Unknown date: Laboratory data included blood cholesterol result was high and blood pressure result was abnormal.

**23. OTHER RELEVANT HISTORY continued**

From/To Dates	Type of History / Notes	Description
Unknown to Ongoing	Current Condition	Forgetfulness (Memory impairment);